IFITM1 is a tight junction protein that inhibits hepatitis C virus entry

Hepatology

Volumn 57, Issue 2, 2013, Pages 461-469

  Wilkins, Courtney ^a   Woodward, Jessica ^a   Lau, Daryl T Y ^b   Barnes, Amy ^c   Joyce, Michael ^d   McFarlane, Nicola ^d   McKeating, Jane A ^c   Tyrrell, D Lorne ^d   Gale, Michael ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD81 ANTIGEN; INTERFERON; INTERFERON INDUCED TRANSMEMBRANE PROTEIN 1; MEMBRANE PROTEIN; OCCLUDIN; TIGHT JUNCTION PROTEIN; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; LIVER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; TIGHT JUNCTION; VIRUS ENTRY;

ANTIGENS, CD81; ANTIGENS, DIFFERENTIATION; ANTIVIRAL AGENTS; CELLS, CULTURED; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON TYPE I; RECEPTORS, VIRUS; TIGHT JUNCTION PROTEINS; VIRUS REPLICATION;

EID: 84873292281     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26066     Document Type: Article

References (39)

1. Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 29(Suppl. 1): 74-81.
2. Kieffer TL, Sarrazin C, Miller JS, Welker MW, Forestier N, Reesink HW, et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. HEPATOLOGY 2007; 46: 631-639.
3. Wilkins C, Gale M Jr. Recognition of viruses by cytoplasmic sensors. Curr Opin Immunol 2010; 22: 41-47.
4. Gale M Jr. Effector genes of interferon action against hepatitis C virus. HEPATOLOGY 2003; 37: 975-978.
5. Wang C, Pflugheber J, Sumpter R Jr, Sodora DL, Hui D, Sen GC, et al. Alpha interferon induces distinct translational control programs to suppress hepatitis C virus RNA replication. J Virol 2003; 77: 3898-3912.
6. Jiang D, Guo H, Xu C, Chang J, Gu B, Wang L, et al. Identification of three interferon-inducible cellular enzymes that inhibit the replication of hepatitis C virus. J Virol 2008; 82: 1665-1678.
7. Helbig KJ, Eyre NS, Yip E, Narayana S, Li K, Fiches G, et al. The antiviral protein viperin inhibits hepatitis C virus replication via interaction with nonstructural protein 5A. HEPATOLOGY 2011; 54: 1506-1517.
8. Schoggins JW, Rice CM. Interferon-stimulated genes and their antiviral effector functions. Curr Opin Virol 2011; 1: 519-525.
9. Zhao H, Lin W, Kumthip K, Cheng D, Fusco DN, Hofmann O, et al. A functional genomic screen reveals novel host genes that mediate interferon-alpha's effects against hepatitis C virus. J Hepatol 2012; 56: 326-333.
10. Metz P, Dazert E, Ruggieri A, Mazur J, Kaderali L, Kaul A, et al. Identification of type I and type II interferon-induced effectors controlling hepatitis C virus replication. HEPATOLOGY 2012; doi: 10.1002/hep.25908.
11. Joshi S, Kaur S, Kroczynska B, Platanias LC. Mechanisms of mRNA translation of interferon stimulated genes. Cytokine 2010; 52: 123-127.
12. Yamamoto S, Yano H, Sanou O, Ikegami H, Kurimoto M, Kojiro M. Different antiviral activities of IFN-alpha subtypes in human liver cell lines: synergism between IFN-alpha2 and IFN-alpha8. Hepatol Res 2002; 24: 99.
13. Erickson AK, Gale M Jr. Regulation of interferon production and innate antiviral immunity through translational control of IRF-7. Cell Res 2008; 18: 433-435.
14. Brass AL, Huang IC, Benita Y, John SP, Krishnan MN, Feeley EM, et al. The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. Cell 2009; 139: 1243-1254.
15. Lu J, Pan Q, Rong L, He W, Liu SL, Liang C. The IFITM proteins inhibit HIV-1 infection. J Virol 2011; 85: 2126-2137.
16. Raychoudhuri A, Shrivastava S, Steele R, Kim H, Ray R, Ray RB. ISG56 and IFITM1 proteins inhibit hepatitis C virus replication. J Virol 2011; 85: 12881-12889.
17. Reid LE, Brasnett AH, Gilbert CS, Porter AC, Gewert DR, Stark GR, et al. A single DNA response element can confer inducibility by both alpha- and gamma-interferons. Proc Natl Acad Sci U S A 1989; 86: 840-844.
18. Yang G, Xu Y, Chen X, Hu G. IFITM1 plays an essential role in the antiproliferative action of interferon-gamma. Oncogene 2007; 26: 594-603.
19. Levy S, Todd SC, Maecker HT. CD81 (TAPA-1): a molecule involved in signal transduction and cell adhesion in the immune system. Annu Rev Immunol 1998; 16: 89-109.
20. Zeisel MB, Fofana I, Fafi-Kremer S, Baumert TF. Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies. J Hepatol 2011; 54: 566-576.
21. Harris HJ, Davis C, Mullins JG, Hu K, Goodall M, Farquhar MJ, et al. Claudin association with CD81 defines hepatitis C virus entry. J Biol Chem 2010; 285: 21092-21102.
22. Mee CJ, Harris HJ, Farquhar MJ, Wilson G, Reynolds G, Davis C, et al. Polarization restricts hepatitis C virus entry into HepG2 hepatoma cells. J Virol 2009; 83: 6211-6221.
23. Sumpter R Jr, Loo YM, Foy E, Li K, Yoneyama M, Fujita T, et al. Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. J Virol 2005; 79: 2689-2699.
24. Kato T, Date T, Murayama A, Morikawa K, Akazawa D, Wakita T. Cell culture and infection system for hepatitis C virus. Nat Protoc 2006; 1: 2334-2339.
25. Martensen PM, Justesen J. Small ISGs coming forward. J Interferon Cytokine Res 2004; 24: 1-19.
26. Witteveldt J, Evans MJ, Bitzegeio J, Koutsoudakis G, Owsianka AM, Angus AG, et al. CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells. J Gen Virol 2009; 90: 48-58.
27. Cormier EG, Tsamis F, Kajumo F, Durso RJ, Gardner JP, Dragic T. CD81 is an entry coreceptor for hepatitis C virus. Proc Natl Acad Sci U S A 2004; 101: 7270-7274.
28. Takahashi S, Doss C, Levy S, Levy R. TAPA-1, the target of an antiproliferative antibody, is associated on the cell surface with the Leu-13 antigen. J Immunol 1990; 145: 2207-2213.
29. Decaens C, Durand M, Grosse B, Cassio D. Which in vitro models could be best used to study hepatocyte polarity? Biol Cell 2008; 100: 387-398.
30. Stevenson BR, Siliciano JD, Mooseker MS, Goodenough DA. Identification of ZO-1: a high molecular weight polypeptide associated with the tight junction (zonula occludens) in a variety of epithelia. J Cell Biol 1986; 103: 755-766.
31. Yap AS, Brieher WM, Gumbiner BM. Molecular and functional analysis of cadherin-based adherens junctions. Annu Rev Cell Dev Biol 1997; 13: 119-146.
32. Mercer DF, Schiller DE, Elliott JF, Douglas DN, Hao C, Rinfret A, et al. Hepatitis C virus replication in mice with chimeric human livers. Nat Med 2001; 7: 927-933.
33. Walters KA, Joyce MA, Thompson JC, Smith MW, Yeh MM, Proll S, et al. Host-specific response to HCV infection in the chimeric SCID-beige/Alb-uPA mouse model: role of the innate antiviral immune response. PLoS Pathog 2006; 2: e59.
34. Huang IC, Bailey CC, Weyer JL, Radoshitzky SR, Becker MM, Chiang JJ, et al. Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus. PLoS Pathog 2011; 7: e1001258.
35. Thali M. Tetraspanin functions during HIV-1 and influenza virus replication. Biochem Soc Trans 2011; 39: 529-531.
36. Gordon-Alonso M, Yanez-Mo M, Barreiro O, Alvarez S, Munoz-Fernandez MA, Valenzuela-Fernandez A, et al. Tetraspanins CD9 and CD81 modulate HIV-1-induced membrane fusion. J Immunol 2006; 177: 5129-5137.
37. Konig R, Stertz S, Zhou Y, Inoue A, Hoffmann HH, Bhattacharyya S, et al. Human host factors required for influenza virus replication. Nature 2010; 463: 813-817.
38. Fanaei M, Monk PN, Partridge LJ. The role of tetraspanins in fusion. Biochem Soc Trans 2011; 39: 524-528.
39. Coyne CB, Bergelson JM. CAR: a virus receptor within the tight junction. Adv Drug Deliv Rev 2005; 57: 869-882.